Invitrogen™ Necitumumab Recombinant Human Monoclonal Antibody

Human Recombinant Monoclonal Antibody

Supplier:  Invitrogen™ MA541880

Catalog No. PIMA541880

Description

Endotoxin level < 0.01EU/μg by LAL method Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 °C for one week. Store at -20 to -80 °C for twelve months from the date of receipt.

Necitumumab is an intravenously administered recombinant monoclonal IgG1 antibody used in the treatment of non-small cell lung cancer (NSCLC) as an EGFR antagonist. It functions by binding to epidermal growth factor receptor (EGFR) and prevents binding of its ligands, a process that is involved in cell proliferation, metastasis, angiogenesis, and malignant progression. Binding of necitumumab to EGFR induces receptor internalization and degradation, thereby preventing further activation of EGFR which is beneficial in NSCLC as many patients have increased protein expression of EGFR. Necitumumab is approved for use in combination with cisplatin and gemcitabine as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC).

Specifications

• Antigen: Necitumumab
• Classification: Recombinant Monoclonal
• Conjugate: Unconjugated
• Gene Alias: 11F8; IMC-11F8; LY3012211
• Immunogen: Human EGFR/ERBB1.
• Quantity: 100 μg
• Primary or Secondary: Primary
• Content And Storage: -20°C, Avoid Freeze/Thaw Cycles
• Form: Liquid
• Target Molecule: Chemical

• Applications: ELISA, SDS-Page
• Concentration: 2.5 mg/mL
• Formulation: PBS with no preservative; pH 7.5
• Host Species: Human
• Purification Method: Protein A
• Regulatory Status: RUO
• Target Species: Human
• Product Type: Antibody
• Isotype: IgG1 κ